Search

Your search keyword '"Gehrmann, M"' showing total 253 results
Start Over Author "Gehrmann, M"
253 results on '"Gehrmann, M"'

2. Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer—comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial

Author

Schmidt, M., Victor, A., Bratzel, D., Boehm, D., Cotarelo, C., Lebrecht, A., Siggelkow, W., Hengstler, J.G., Elsäßer, A., Gehrmann, M., Lehr, H.-A., Koelbl, H., von Minckwitz, G., Harbeck, N., and Thomssen, C.

Published
2009
Full Text
View/download PDF

13. Implementing Reverse Phase Protein Array Profiling as a Sensitive Method for the Early Pre-Clinical Detection of Off-Target Toxicities Associated with Sunitinib Malate

Author

O'Farrell, A.C., Miller, I.S., Evans, R., Alamanou, M., Cary, M., Udupi, G. Mallya, Lafferty, A., Monsefi, N., Cremona, M., Prehn, J.H.M., Verheul, H.M.W., Gallagher, W.M., Gehrmann, M., Byrne, A.T., O'Farrell, A.C., Miller, I.S., Evans, R., Alamanou, M., Cary, M., Udupi, G. Mallya, Lafferty, A., Monsefi, N., Cremona, M., Prehn, J.H.M., Verheul, H.M.W., Gallagher, W.M., Gehrmann, M., and Byrne, A.T.

Abstract

Item does not contain fulltext, PURPOSE: The tyrosine kinase inhibitor (TKI) sunitinib is a multi-targeted agent approved across multiple cancer indications. Nevertheless, since approval, data has emerged to describe a worrisome side effect profile including hypertension, hand-foot syndrome, fatigue, diarrhea, mucositis, proteinuria, and (rarely) congestive heart failure. It has been hypothesized that the observed multi-parameter toxicity profile is related to "on-target" kinase inhibition in "off-target" tissues. EXPERIMENTAL DESIGN: To interrogate off-target effects in pre-clinical studies, a reverse phase protein array (RPPA) approach is employed. Mice are treated with sunitinib (40 mg kg(-1) ) for 4 weeks, following which critical organs are removed. The Zeptosens RPPA platform is employed for protein expression analysis. RESULTS: Differentially expressed proteins associated with damage and/or stress are found in the majority of organs from treated animals. Proteins differentially expressed in the heart are associated with myocardial hypertrophy, ischaemia/reperfusion, and hypoxia. However, hypertrophy is not evidenced on histology. Mild proteinuria is observed; however, no changes in renal glomerular structure are visible via electron microscopy. In skin, proteins associated with cutaneous inflammation, keratinocyte hyper-proliferation, and increased inflammatory response are differentially expressed. CONCLUSIONS AND CLINICAL RELEVANCE: It is posited that pre-clinical implementation of a combined histopathological/RPPA approach provides a sensitive method to mechanistically elucidate the early manifestation of TKI on-target/organ off-target toxicities.

Published
2019

15. Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer—comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial

Author

Schmidt, M., Victor, A., Bratzel, D., Boehm, D., Cotarelo, C., Lebrecht, A., Siggelkow, W., Hengstler, J. G., Elsäßer, A., Gehrmann, M., Lehr, H. -A, Koelbl, H., von Minckwitz, G., Harbeck, N., Thomssen, C., Schmidt, M., Victor, A., Bratzel, D., Boehm, D., Cotarelo, C., Lebrecht, A., Siggelkow, W., Hengstler, J. G., Elsäßer, A., Gehrmann, M., Lehr, H. -A, Koelbl, H., von Minckwitz, G., Harbeck, N., and Thomssen, C.

Abstract

Background: Defining risk categories in breast cancer is of considerable clinical significance. We have developed a novel risk classification algorithm and compared its prognostic utility to the Web-based tool Adjuvant! and to the St Gallen risk classification. Patients and methods: After a median follow-up of 10 years, we retrospectively analyzed 410 consecutive node-negative breast cancer patients who had not received adjuvant systemic therapy. High risk was defined by any of the following criteria: (i) age <35 years, (ii) grade 3, (iii) human epithelial growth factor receptor-2 positivity, (iv) vascular invasion, (v) progesterone receptor negativity, (vi) grade 2 tumors >2 cm. All patients were also characterized using Adjuvant! and the St Gallen 2007 risk categories. We analyzed disease-free survival (DFS) and overall survival (OS). Results: The Node-Negative-Breast Cancer-3 (NNBC-3) algorithm enlarged the low-risk group to 37% as compared with Adjuvant! (17%) and St Gallen (18%), respectively. In multivariate analysis, both Adjuvant! [P = 0.027, hazard ratio (HR) 3.81, 96% confidence interval (CI) 1.16-12.47] and the NNBC-3 risk classification (P = 0.049, HR 1.95, 95% CI 1.00-3.81) significantly predicted OS, but only the NNBC-3 algorithm retained its prognostic significance in multivariate analysis for DFS (P < 0.0005). Conclusion: The novel NNBC-3 risk algorithm is the only clinicopathological risk classification algorithm significantly predicting DFS as well as OS

Published
2017

17. Multi-channel ultra-wideband radar sounder and imager

Author

Hale, R., primary, Miller, H., additional, Gogineni, S., additional, Yan, J. B., additional, Rodriguez-Morales, F., additional, Leuschen, C., additional, Paden, J., additional, Li, J., additional, Binder, T., additional, Steinhage, D., additional, Gehrmann, M., additional, and Braaten, D., additional

Published
2016
Full Text
View/download PDF

20. Membrane Hsp70 expression, a histological marker for primary glioblastoma is elevated in patients' serum samples

Author

Thorsteinsdottir, J, Fu, P, Gehrmann, M, Multhoff, G, Tonn, JC, and Schichor, C

Subjects
Gliom, marker, ddc: 610, glioma, 610 Medical sciences, Medicine, Hsp70
Abstract

Objective: Tumor cells, in contrast to non-neoplastic cells, have the capacity to translocate cytosolic heat shock protein 70 (Hsp70) on their plasma membrane in different cancer types where it can be detected specifically by cmHsp70.1 monoclonal antibody. The biological function of membrane Hsp70 remains[for full text, please go to the a.m. URL], 63. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Japanischen Gesellschaft für Neurochirurgie (JNS)

Published
2012
Full Text
View/download PDF

25. Membrane bound Hsp70 expression in gliomas: a novel, hypoxia-related marker for progression

Author

Thorsteinsdottir, J, Fu, P, Guo, K, Gehrmann, M, Multhoff, G, and Schichor, C

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Objective: Heat-shock-binding-protein 70 (Hsp70) is localized in the cytosol of cells under physiological conditions and regulates folding/unfolding of proteins in order to function as a molecular chaperone to protect cells from lethal damage. In a variety of non-glial tumor entities, Hsp70 is [for full text, please go to the a.m. URL], 62. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Polnischen Gesellschaft für Neurochirurgen (PNCH)

Published
2011
Full Text
View/download PDF

26. New prognostic and predictive factors in breast cancer

Author

Schmidt M, Gehrmann M, Jan Hengstler, and Koelbl H

Subjects
Genetic Markers, Evidence-Based Medicine, Serine Proteinase Inhibitors, Receptor, ErbB-2, Breast Neoplasms, Prognosis, Risk Assessment, Sensitivity and Specificity, Urokinase-Type Plasminogen Activator, Receptors, Estrogen, Predictive Value of Tests, Plasminogen Activator Inhibitor 1, Humans, Female, Molecular Targeted Therapy
Abstract

There are two major questions regarding systemic therapy of breast cancer: Firstly, which patients should be treated, and secondly, how should these patients be treated? Prognostic factors aim to foresee the outcome of patients irrespective of treatment while predictive factors intend to assess the outcome of patients receiving a certain systemic therapy and thus are intimately associated with sensitivity or resistance to therapy. Ideally, a predictive factor is also a therapeutic target as it is the case with estrogen receptor (ER) or HER-2. In order to avoid over- as well as under-treatment, it is advisable to select the appropriate treatment strategy on the basis of a careful risk assessment for each individual patient. Additionally to time-honoured clinicopathological factors additional prognostic factors like urokinase-type plasminogen activator (uPA)/plasminogen activator inhibitor 1 (PAI-1) or multiparameter gene-expression analyses have shown promising results especially in node-negative breast cancer. These multigene profiles offer new insights in breast cancer biology, like the important role of the tumor-associated immune system. ER, HER-2 and potentially newer prognostic factors like epithelial cell adhesion molecule (Ep-CAM) bridge the gap from prognosis to prediction and serve as therapeutic targets. This should allow us to quantify the risk of progression in each individual patient and tailor treatment accordingly, leading to a more personalized treatment recommendation.

Published
2010

29. Radiation induced stress proteins

Author

Gehrmann M, Michael Molls, Daniela Schilling, and Gabriele Multhoff

Subjects
Pharmacology, Necrosis, Lung, medicine.medical_treatment, Phosphatidylserines, Phosphatidylserine, Hypoxia (medical), Biology, Molecular biology, Cell Hypoxia, Hsp70, Radiation therapy, chemistry.chemical_compound, medicine.anatomical_structure, Membrane, chemistry, Apoptosis, Cell Line, Tumor, Neoplasms, medicine, Humans, HSP70 Heat-Shock Proteins, Pharmacology (medical), medicine.symptom
Abstract

The major heat-inducible member of thestress proteins with a molecular weight ofabout 70 kDa (Heat shock protein 70, Hsp70)is a ubiquitous protein contributing to a num-berofcellularprocessesincludingtheprotec-tion of cells from apoptosis induced by envi-ronmental stress. Recently, we and otherscould show that a variety of tumor cells, incontrast to normal tissues, have the uniquefeature of expressing Hsp70 on their plasmamembrane [1]. Monitoring the clinical out-come (up to 5 years) demonstrated a negativecorrelation between the Hsp70 membranestatusandtheoverallsurvivalinpatientswithlowerrectalandsquamouscellcarcinomasofthe lung [2].In a recent study we were able to track theexpressionofHsp70locatedinthemembraneof tumor cells before and after stress [3]. Innon-stressed tumor cells Hsp70 is associatedwith Bag-4 [4] and the lipid-raft compoundglobotriaosylceramide (Gb3) in the plasmamembrane [5].Hypoxia is known to limit the therapeuticefficacy of radiation therapy. Therefore, weaddressed the question whether hypoxiamight affect the Hsp70 membrane expres-sion. In hypoxic tumor cells the Hsp70 mem-brane expression is elevated and Hsp70 isco-located with phosphatidylserine (PS) inthe plasma membrane.

Published
2010
Full Text
View/download PDF

32. Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules

Author

Universitat Rovira i Virgili, Teschendorff AE, Gomez S, Arenas A, El-Ashry D, Schmidt M, Gehrmann M, Caldas C., Universitat Rovira i Virgili, and Teschendorff AE, Gomez S, Arenas A, El-Ashry D, Schmidt M, Gehrmann M, Caldas C.

Abstract

Background: Elucidating the activation pattern of molecular pathways across a given tumour type is a key challenge necessary for understanding the heterogeneity in clinical response and for developing novel more effective therapies. Gene expression signatures of molecular pathway activation derived from perturbation experiments in model systems as well as structural models of molecular interactions (model signatures) constitute an important resource for estimating corresponding activation levels in tumours. However, relatively few strategies for estimating pathway activity from such model signatures exist and only few studies have used activation patterns of pathways to refine molecular classifications of cancer. Methods: Here we propose a novel network-based method for estimating pathway activation in tumours from model signatures. We find that although the pathway networks inferred from cancer expression data are highly consistent with the prior information contained in the model signatures, that they also exhibit a highly modular structure and that estimation of pathway activity is dependent on this modular structure. We apply our methodology to a panel of 438 estrogen receptor negative (ER-) and 785 estrogen receptor positive (ER+) breast cancers to infer activation patterns of important cancer related molecular pathways. Results: We show that in ER negative basal and HER2+ breast cancer, gene expression modules reflecting T-cell helper-1 (Th1) and T-cell helper-2 (Th2) mediated immune responses play antagonistic roles as major risk factors for distant metastasis. Using Boolean interaction Cox-regression models to identify non-linear pathway combinations associated with clinical outcome, we show that simultaneous high activation of Th1 and low activation of a TGF-be

Published
2010

36. Tumor-Specific Hsp70 Plasma Membrane Localization Is Enabled by the Glycosphingolipid Gb3

Author

Klefstrom, J, Gehrmann, M, Liebisch, G, Schmitz, G, Anderson, R, Steinem, C, De Maio, A, Pockley, G, Multhoff, G, Klefstrom, J, Gehrmann, M, Liebisch, G, Schmitz, G, Anderson, R, Steinem, C, De Maio, A, Pockley, G, and Multhoff, G

Abstract

BACKGROUND: Human tumors differ from normal tissues in their capacity to present Hsp70, the major stress-inducible member of the HSP70 family, on their plasma membrane. Membrane Hsp70 has been found to serve as a prognostic indicator of overall patient survival in leukemia, lower rectal and non small cell lung carcinomas. Why tumors, but not normal cells, present Hsp70 on their cell surface and the impact of membrane Hsp70 on cancer progression remains to be elucidated. METHODOLOGY/PRINCIPAL FINDINGS: Although Hsp70 has been reported to be associated with cholesterol rich microdomains (CRMs), the partner in the plasma membrane with which Hsp70 interacts has yet to be identified. Herein, global lipid profiling demonstrates that Hsp70 membrane-positive tumors differ from their membrane-negative counterparts by containing significantly higher amounts of globotriaoslyceramide (Gb3), but not of other lipids such as lactosylceramide (LacCer), dodecasaccharideceramide (DoCer), galactosylceramide (GalCer), ceramide (Cer), or the ganglioside GM1. Apart from germinal center B cells, normal tissues are Gb3 membrane-negative. Co-localization of Hsp70 and Gb3 was selectively determined in Gb3 membrane-positive tumor cells, and these cells were also shown to bind soluble Hsp70-FITC protein from outside in a concentration-dependent manner. Given that the latter interaction can be blocked by a Gb3-specific antibody, and that the depletion of globotriaosides from tumors reduces the amount of membrane-bound Hsp70, we propose that Gb3 is a binding partner for Hsp70. The in vitro finding that Hsp70 predominantly binds to artificial liposomes containing Gb3 (PC/SM/Chol/Gb3, 17/45/33/5) confirms that Gb3 is an interaction partner for Hsp70. CONCLUSIONS/SIGNIFICANCE: These data indicate that the presence of Gb3 enables anchorage of Hsp70 in the plasma membrane of tumors and thus they might explain tumor-specific membrane localization of Hsp70.

Published
2008

39. Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer

Author

Darb-Esfahani, S, primary, Kronenwett, R, additional, von Minckwitz, G, additional, Denkert, C, additional, Gehrmann, M, additional, Rody, A, additional, Budczies, J, additional, Brase, J C, additional, Mehta, M K, additional, Bojar, H, additional, Ataseven, B, additional, Karn, T, additional, Weiss, E, additional, Zahm, D M, additional, Khandan, F, additional, Dietel, M, additional, and Loibl, S, additional

Published
2012
Full Text
View/download PDF

40. LAB-OMICS AND PROGNOSTIC MARKERS

Author

Jensen, R. L., primary, Abraham, S., additional, Hu, N., additional, Jensen, R. L., additional, Boulay, J.-L., additional, Leu, S., additional, Frank, S., additional, Vassella, E., additional, Vajtai, I., additional, von Felten, S., additional, Taylor, E., additional, Schulz, M., additional, Hutter, G., additional, Sailer, M., additional, Hench, J., additional, Mariani, L., additional, van Thuijl, H. F., additional, Scheinin, I., additional, van Essen, D. F., additional, Heimans, J. J., additional, Wesseling, P., additional, Ylstra, B., additional, Reijneveld, J. C., additional, Borges, A. R., additional, Larrubia, P. L., additional, Marques, J. M. B., additional, Cerdan, S. G., additional, Brastianos, P., additional, Horowitz, P., additional, Santagata, S., additional, Jones, R. T., additional, McKenna, A., additional, Getz, G., additional, Ligon, K., additional, Palescandolo, E., additional, Van Hummelen, P., additional, Stemmer-Rachamimov, A., additional, Louis, D., additional, Hahn, W. C., additional, Dunn, I., additional, Beroukhim, R., additional, Guan, X., additional, Vengoechea, J., additional, Zheng, S., additional, Sloan, A., additional, Chen, Y., additional, Brat, D., additional, O'Neill, B. P., additional, Cohen, M., additional, Aldape, K., additional, Rosenfeld, S., additional, Noushmehr, H., additional, Verhaak, R. G., additional, Barnholtz-Sloan, J., additional, Bahassi, E. M., additional, Li, Y.-Q., additional, Cross, E., additional, Li, W., additional, Vijg, J., additional, McPherson, C., additional, Warnick, R., additional, Stambrook, P., additional, Rixe, O., additional, Manterola, L., additional, Tejada-Solis, S., additional, Diez-Valle, R., additional, Gonzalez, M., additional, Jauregui, P., additional, Sampron, N., additional, Barrena, C., additional, Ruiz, I., additional, Gallego, J., additional, Delattre, J.-Y., additional, de Munain, A. L., additional, Mlonso, M. M., additional, Saito, K., additional, Mukasa, A., additional, Nagae, G., additional, Aihara, K., additional, Takayanagi, S., additional, Aburatani, H., additional, Saito, N., additional, Kong, X.-T., additional, Fu, B. D., additional, Du, S., additional, Hasso, A. N., additional, Linskey, M. E., additional, Bota, D., additional, Li, C., additional, Chen, Y.-S., additional, Chen, Z.-p., additional, Kim, C. H., additional, Cheong, J. H., additional, Kim, J. M., additional, Yelon, N. P., additional, Jacoby, E., additional, Cohen, Z. R., additional, Ishida, J., additional, Kurozumi, K., additional, Ichikawa, T., additional, Onishi, M., additional, Fujii, K., additional, Shimazu, Y., additional, Date, I., additional, Narayanan, R., additional, Ho, Q. H., additional, Levin, B. S., additional, Maeder, M. L., additional, Joung, J. K., additional, Nutt, C. L., additional, Louis, D. N., additional, Thorsteinsdottir, J., additional, Fu, P., additional, Gehrmann, M., additional, Multhoff, G., additional, Tonn, J.-C., additional, Schichor, C., additional, Thirumoorthy, K., additional, Gordon, N., additional, Walston, S., additional, Patel, D., additional, Okamoto, M., additional, Chakravarti, A., additional, Palanichamy, K., additional, French, P., additional, Erdem, L., additional, Gravendeel, L., additional, de Rooi, J., additional, Eilers, P., additional, Idbaih, A., additional, Spliet, W., additional, den Dunnen, W., additional, Teepen, J., additional, Smitt, P. S., additional, Kros, J. M., additional, Gorlia, T., additional, van den Bent, M., additional, McCarthy, D., additional, Cook, R. W., additional, Oelschlager, K., additional, Maetzold, D., additional, Hanna, M., additional, Wick, W., additional, Meisner, C., additional, Hentschel, B., additional, Platten, M., additional, Sabel, M. C., additional, Koeppen, S., additional, Ketter, R., additional, Weiler, M., additional, Tabatabai, G., additional, Schilling, A., additional, von Deimling, A., additional, Gramatzki, D., additional, Westphal, M., additional, Schackert, G., additional, Loeffler, M., additional, Simon, M., additional, Reifenberger, G., additional, Weller, M., additional, Moren, L., additional, Johansson, M., additional, Bergenheim, T., additional, Antti, H., additional, Sulman, E. P., additional, Goodman, L. D., additional, Wani, K. M., additional, DeMonte, F., additional, Aldape, K. D., additional, Krischek, B., additional, Gugel, I., additional, Aref, D., additional, Marshall, C., additional, Croul, S., additional, Zadeh, G., additional, Nilsson, C. L., additional, Sulman, E., additional, Liu, H., additional, Wild, C., additional, Lichti, C. F., additional, Emmett, M. R., additional, Lang, F. F., additional, Conrad, C., additional, Alentorn, A., additional, Marie, Y., additional, Boisselier, B., additional, Carpetier, C., additional, Mokhtari, K., additional, Hoang-Xuan, K., additional, Capelle, L., additional, Lautenschlaeger, T., additional, Huebner, A., additional, McIntyre, J. B., additional, Magliocco, T., additional, Hamilton, M., additional, Easaw, J., additional, Pollo, B., additional, Calatozzolo, C., additional, Vuono, R., additional, Guzzetti, S., additional, Eoli, M., additional, Silvani, A., additional, Di Meco, F., additional, Filippini, G., additional, Finocchiaro, G., additional, Joy, A., additional, Ramesh, A., additional, Smirnov, I., additional, Reiser, M., additional, Shapiro, W., additional, Mills, G., additional, Kim, S., additional, Feuerstein, B., additional, Gonda, D. D., additional, Li, J., additional, McCabe, N., additional, Walker, S., additional, Goffard, N., additional, Wikstrom, K., additional, McLean, E., additional, Greenan, C., additional, Delaney, T., additional, McCarthy, M., additional, McDyer, F., additional, Keating, K. E., additional, James, I. F., additional, Harrison, T., additional, Mullan, P., additional, Harkin, D. P., additional, Carter, B. S., additional, Kennedy, R. D., additional, Chen, C. C., additional, Patel, A. S., additional, Allen, J. E., additional, Dicker, D. T., additional, Rizzo, K., additional, Sheehan, J. M., additional, Glantz, M. J., additional, El-Deiry, W. S., additional, Salhia, B., additional, Ross, J. T., additional, Kiefer, J., additional, Van Cott, C., additional, Metpally, R., additional, Baker, A., additional, Sibenaller, Z., additional, Nasser, S., additional, Ryken, T., additional, Ramanathan, R., additional, Berens, M. E., additional, Carpten, J., additional, Tran, N. L., additional, Bi, Y., additional, Pal, S., additional, Zhang, Z., additional, Gupta, R., additional, Macyszyn, L., additional, Fetting, H., additional, O'Rourke, D., additional, Davuluri, R. V., additional, Ezrin, A. M., additional, Moore, K., additional, Stummer, W., additional, Hadjipanayis, C. G., additional, Cahill, D. P., additional, Beiko, J., additional, Suki, D., additional, Prabhu, S., additional, Weinberg, J., additional, Lang, F., additional, Sawaya, R., additional, Rao, G., additional, McCutcheon, I., additional, Barker, F. G., additional, Trister, A. D., additional, Bot, B., additional, Fontes, K., additional, Bridge, C., additional, Baldock, A. L., additional, Rockhill, J. K., additional, Mrugala, M. M., additional, Rockne, R. R., additional, Huang, E., additional, Swanson, K. R., additional, Underhill, H. R., additional, Zhang, J., additional, Shi, M., additional, Lin, X., additional, Mikheev, A., additional, Rostomily, R. C., additional, Scheck, A. C., additional, Stafford, P., additional, Hughes, A., additional, Cichacz, Z., additional, Coons, S. W., additional, Johnston, S. A., additional, Mainwaring, L., additional, Craig, J., additional, Garcia, D., additional, Bergthold, G., additional, Burns, M., additional, Rich, B., additional, Ramkissoon, S., additional, Eberhart, C., additional, Ligon, A., additional, Goumnerova, L., additional, Stiles, C., additional, Kieran, M., additional, Hahn, W., additional, Olausson, K. H., additional, Correia, J., additional, Gafni, E., additional, Theisen, M., additional, Hayashi, M., additional, Haidar, S., additional, Maire, C., additional, Mainwaring, L. A., additional, Norden, A., additional, Wen, P., additional, Kung, A., additional, Alexander, B., additional, Tonellato, P., additional, and Ligon, K. L., additional

Published
2012
Full Text
View/download PDF

47. Abstract P3-10-07: T5 Is a New Molecular Predictor of Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Author

Filipits, M, primary, Rudas, M, additional, Jakesz, R, additional, Dubsky, P, additional, Singer, CF, additional, Dietze, O, additional, Greil, R, additional, Jelen, A, additional, Sevelda, P, additional, Freibauer, C, additional, Fitzal, F, additional, Müller, V, additional, Jänicke, F, additional, Schmidt, M, additional, Kölbl, H, additional, Rody, A, additional, Kaufmann, M, additional, Schroth, W, additional, Schwab, M, additional, Brauch, H, additional, Weber, K, additional, Feder, I, additional, Hennig, G, additional, Gehrmann, M, additional, and Gnant, MFX., additional

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results